Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha 1-adrenergic receptor subtypes

K P Minneman1, T A Esbenshade

  • 1Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322.

Annual Review of Pharmacology and Toxicology
|January 1, 1994
PubMed
Summary

Understanding alpha 1-adrenergic receptor (AR) subtypes remains challenging due to ongoing debate about their exact number and signaling. Further research is needed to clarify these receptors for potential therapeutic advancements.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties.

British journal of pharmacology·2009
Same author

Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists.

British journal of pharmacology·2009
Same author

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

British journal of pharmacology·2008
Same author

Minimization of potential hERG liability in histamine H3 receptor antagonists.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2008
Same author

Pharmacological classification of histamine H3 receptor agents across species is attributable to transmembrane 3 sequence differences.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2007
Same author

A new family of histamine H3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2007

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Adrenergic Receptor Research

Background:

  • There is no consensus on the number and signaling mechanisms of alpha 1-adrenergic receptor (AR) subtypes.
  • Pharmacological studies distinguish two native subtypes (alpha 1A and alpha 1B), while molecular cloning has identified three subtypes (alpha 1B, alpha 1C, and alpha 1D).
  • The precise relationship between cloned receptors and native subtypes is unclear, with the alpha 1A subtype likely not yet cloned.

Purpose of the Study:

  • To clarify the number and properties of alpha 1-adrenergic receptor (AR) subtypes.
  • To understand the relationship between cloned receptors and native subtypes.
  • To define the drug specificities and second messenger pathways of alpha 1-AR subtypes.

Main Methods:

  • Molecular cloning of complementary DNA sequences for remaining alpha 1-AR subtypes.
  • Pharmacological characterization of receptor subtypes.
  • Investigation of cellular and tissue distribution, developmental profiles, and functional importance.

Main Results:

  • Current data suggest the pharmacologically defined alpha 1A subtype has not yet been cloned.
  • Discrepancies exist between pharmacologically identified and cloned alpha 1-adrenergic receptor (AR) subtypes.
  • Significant knowledge gaps remain regarding the distribution and function of alpha 1-AR subtypes.

Conclusions:

  • Clarifying the complexity of alpha 1-adrenergic receptor (AR) subtypes is crucial for defining their properties.
  • Molecular cloning efforts are essential to resolve the number and characteristics of these receptor subtypes.
  • Selective drugs targeting specific alpha 1-AR subtypes hold therapeutic potential for diseases like benign prostatic hyperplasia, though their impact requires further definition.

Related Experiment Videos